TrialNature medicine2026

CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial.

John F DiPersio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.